High dose group

DRUG4 trials

Sponsors

Ahon Pharmaceutical Co., Ltd., José Antonio Hurtado Suazo, Beijing Tiantan Hospital, Kyambadde Ronald

Conditions

Advanced Breast CancerIntraventricular HemorrhageNecrotizing EnterocolitisPaediatricsPremature Infants

Phase 1

Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects

CompletedNCT06290466

Ahon Pharmaceutical Co., Ltd.Advanced Breast Cancer

Start: 2022-11-11End: 2023-02-08Updated: 2024-03-04

rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage

RecruitingNCT06814964

Beijing Tiantan HospitalIntraventricular Hemorrhage

Start: 2025-03-01End: 2025-06-01Target: 18Updated: 2025-02-27

Unknown Phase

PREMAPROB. Probiotics to Prevent Necrotizing Enterocolitis

CompletedNCT06501404

José Antonio Hurtado SuazoNecrotizing Enterocolitis, Premature Infants

Start: 2015-01-10End: 2020-03-20Updated: 2024-07-15

High-dose vs. standard-dose caffeine therapy for apnea of prematurity.

Active, not recruitingPACTR202604505368563

Kyambadde RonaldPaediatrics

Start: 2025-10-21Target: 122Updated: 2026-06-22

Related Papers

No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects

Frontiers in Pharmacology2024-08-121 citations